PMID- 27457726
OWN - NLM
STAT- MEDLINE
DCOM- 20170324
LR  - 20220113
IS  - 1476-511X (Electronic)
IS  - 1476-511X (Linking)
VI  - 15
DP  - 2016 Jul 26
TI  - Homocysteine diminishes apolipoprotein A-I function and expression in patients 
      with hypothyroidism: a cross-sectional study.
PG  - 123
LID - 10.1186/s12944-016-0293-5 [doi]
LID - 123
AB  - BACKGROUND: Hypothyroidism (HO) can significantly impair lipid metabolism and 
      increase cardiovascular disease risk. Hyperhomocysteinemia (HHcy) is an 
      independent risk factor for cardiovascular disease. Our previous study 
      demonstrated that HHcy significantly induced insulin resistance and impaired 
      coronary artery endothelial function in patients with either hypertension or HO. 
      In the present study, we studied whether plasma levels of high-density 
      lipoprotein-cholesterol (HDL-C) and apolipoprotein A-I (Apo A-I) were altered in 
      patients with HO, and if so, whether this change was mediated by HHcy. METHODS: A 
      total of 258 subjects were enrolled and divided into the following three groups: 
      control group (n = 94), HO group (n = 73), and subclinical hypothyroidism (SHO) 
      group (n = 91). Additionally, all groups were subdivided based on the subjects' 
      Hcy levels into HHcy (plasma Hcy level over 15 mumol/l) and normal Hcy subgroups. 
      The plasma levels of lipid indexes were measured. Statistical analyses were 
      performed to evaluate the correlations between groups. RESULTS: The plasma Hcy 
      levels were significantly higher in the HO group than in the SHO or control 
      groups (all p < 0.05). Moreover, levels of Apo A-I and HDL-C were markedly 
      reduced in the HHcy subgroup compared with the normal Hcy subgroup for patients 
      with either HO (Apo A-I: p < 0.05; HDL-C: p < 0.01) or SHO (Apo A-I: p < 0.05; 
      HDL-C: p < 0.01). In addition, the plasma Hcy levels were negatively correlated 
      with levels of Apo A-I in all three groups (HO group: r = - 0.320, SHO group: 
      r = - 0.337 and control group: r = - 0.317; all p < 0.01). CONCLUSIONS: Hcy 
      levels were significantly increased in patients with HO or SHO. These increased 
      Hcy levels may impair cardiovascular function via the inhibition of Apo A-1 
      expression and impairment of its antioxidant capacity. Our findings provide new 
      insights into the pathogenesis of hypothyroidism-induced metabolic disorders.
FAU - Yang, Ning
AU  - Yang N
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University, No. 8, Gongti South Road, Chaoyang district, Beijing, 100020, 
      People's Republic of China.
FAU - Yao, Zhi
AU  - Yao Z
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University, No. 8, Gongti South Road, Chaoyang district, Beijing, 100020, 
      People's Republic of China.
FAU - Miao, Li
AU  - Miao L
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University, No. 8, Gongti South Road, Chaoyang district, Beijing, 100020, 
      People's Republic of China.
FAU - Liu, Jia
AU  - Liu J
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University, No. 8, Gongti South Road, Chaoyang district, Beijing, 100020, 
      People's Republic of China.
FAU - Gao, Xia
AU  - Gao X
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University, No. 8, Gongti South Road, Chaoyang district, Beijing, 100020, 
      People's Republic of China.
FAU - Xu, Yuan
AU  - Xu Y
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University, No. 8, Gongti South Road, Chaoyang district, Beijing, 100020, 
      People's Republic of China.
FAU - Wang, Guang
AU  - Wang G
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University, No. 8, Gongti South Road, Chaoyang district, Beijing, 100020, 
      People's Republic of China. drwg6688@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20160726
PL  - England
TA  - Lipids Health Dis
JT  - Lipids in health and disease
JID - 101147696
RN  - 0 (Apolipoprotein A-I)
RN  - 0 (Cholesterol, HDL)
RN  - 0LVT1QZ0BA (Homocysteine)
SB  - IM
MH  - Adult
MH  - Apolipoprotein A-I/*blood/genetics
MH  - Cholesterol, HDL/*blood
MH  - Cross-Sectional Studies
MH  - Female
MH  - Gene Expression
MH  - Homocysteine/*blood
MH  - Humans
MH  - Hyperhomocysteinemia/*blood/diagnosis/genetics/physiopathology
MH  - Hypothyroidism/*blood/diagnosis/genetics/physiopathology
MH  - Insulin Resistance
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
PMC - PMC4960745
OTO - NOTNLM
OT  - Apolipoprotein A-I
OT  - High-density lipoprotein-cholesterol
OT  - Homocysteine
OT  - Hypothyroidism
EDAT- 2016/07/28 06:00
MHDA- 2017/03/25 06:00
PMCR- 2016/07/26
CRDT- 2016/07/27 06:00
PHST- 2016/04/26 00:00 [received]
PHST- 2016/07/16 00:00 [accepted]
PHST- 2016/07/27 06:00 [entrez]
PHST- 2016/07/28 06:00 [pubmed]
PHST- 2017/03/25 06:00 [medline]
PHST- 2016/07/26 00:00 [pmc-release]
AID - 10.1186/s12944-016-0293-5 [pii]
AID - 293 [pii]
AID - 10.1186/s12944-016-0293-5 [doi]
PST - epublish
SO  - Lipids Health Dis. 2016 Jul 26;15:123. doi: 10.1186/s12944-016-0293-5.